Caroline Koch

Caroline Koch

Auto-generated profile, based on publicly available information

Caroline Koch

Department of Chemistry, Molecular Science Research Hub, Imperial College London, White City Campus

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Molecular Pharmacology
Verified
Journal Article
Closed access
JMJacky Marie
Jacky Marie
CKCaroline Koch
Caroline Koch
DPDidier Pruneau
Didier Pruneau
JPJean-Luc Paquet
Jean-Luc Paquet
TGThierry Groblewski
Thierry Groblewski
JBJean-Claude Bonnafous
Jean-Claude Bonnafous

15 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CKCaroline Koch
Caroline Koch
BRBenedict Reilly-O’donnell
Benedict Reilly-O’donnell
RGRichard Gutierrez
Richard Gutierrez
CLCarla Lucarelli
Carla Lucarelli
FNFu Siong Ng
Fu Siong Ng
JEJoshua B. Edel
Joshua B. Edel
Currently, most blood tests in a clinical setting only investigate a handful of markers. A low-cost, rapid, and highly multiplexed platform for the quantitative detection of blood biomarkers has the potential to advance clinical diagnostics beyond the single biomarker paradigm. In this study, we perform nanopore sequencing of barcoded molecular probes that have been engineered to recognise a panel of biological targets (miRNAs, proteins, and small molecules such as neurotransmitters), allowing for highly multiplexed simultaneous detection. Our workflow is rapid, from sample preparation to results in 1 hour. We also demonstrate that the strategy can be used to detect biomarkers directly from human serum without extraction or amplification. The established method is easily adaptable, as the number and type of targets detected can be greatly expanded depending on the application required.

14 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDan Marks
Dan Marks
EGEdwin Garcia
Edwin Garcia
SKSunil Kumar
Sunil Kumar
KTKatie Tyson
Katie Tyson
CKCaroline Koch
Caroline Koch
IMIain McNeish
Iain McNeish
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionised the treatment of ovarian high grade serous carcinoma (HGSC), especially those with defective homologous recombination. However, the emergence of resistance poses a critical challenge, as over 50% of patients relapse within three years. The mechanisms underlying changes in PARP trapping, a central aspect of PARPi efficacy, are not well understood due to limitations in current experimental methodologies. Existing techniques lack resolution and throughput, impeding efforts to study PARP trapping dynamics over time with single-cell resolution. Effective tools to study PARP trapping in live cells are urgently needed to elucidate resistance mechanisms and inform therapeutic strategies. To address this, we used CRISPR-Cas9 gene editing to dual-label endogenous PARP1 with EGFP and mCherryFP in OVCAR4 cells to develop a novel intramolecular FRET-based biosensor that enables real-time, single-cell visualization of PARP trapping dynamics in live cells. High-content fluorescence lifetime imaging microscopy (FLIM) revealed dose dependent PARP trapping upon exposure to PARP inhibitor and distinguished between the trapping efficiencies of four different PARPi (veliparib, olaparib, rucaparib, talazoparib). Moreover, we found reduced PARP trapping in PARPi-resistant models, both in vitro and in vivo , providing critical evidence for altered PARP trapping as a resistance mechanism and illustrating the potential of this FRET biosensor to interrogate resistance mechanisms quantitatively. This PARP trapping biosensor represents a transformative advance, enabling dynamic, high-resolution analysis of mechanisms underlying cancer drug resistance. It provides critical insights into the heterogeneity of PARPi resistance, with implications for developing more effective therapies and improving personalised treatment strategies for ovarian cancer patients. Graphical

14 October 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
ASAdithi Somayaji
Adithi Somayaji
PMPiyas Mukherjee
Piyas Mukherjee
CKCaroline Koch
Caroline Koch
CCClarissa Prazeres da Costa
Clarissa Prazeres da Costa
YHYoussef Hamway
Youssef Hamway
The global burden of infectious disease is on the rise, driven by antibiotic resistance, emerging pathogens, and gaps in accessible, decentralized diagnostics. To address these demands, there is a need for the development of diagnostic platforms for detection, surveillance, or monitoring assays with quick turnaround times. Oxford Nanopore sequencing, a platform for real-time long-read third-generation sequencing, has emerged as a promising tool in this space, with the ability to detect a wide range of molecular targets, including DNA, RNA, proteins, and base modifications. Its unique advantages, including portability, scalability, and the capacity for culture-independent workflows, combined with the depth of sequencing data produced, make it especially well-suited for infectious disease diagnostics and surveillance in both clinical and field settings. In this review, we aim to critically examine recent advances in the application of nanopore sequencing for diagnosing infectious diseases caused by bacterial, viral, fungal, and parasitic agents, as well as for detecting antimicrobial resistance genes. We also compare its potential advantages over conventional diagnostic methods and explore its expanding role in tracking outbreaks, monitoring pathogens in the environment, and detecting spillover events from animals to humans. Together, these applications highlight the relevance and position of this novel technology as a tool of choice for translational medical research and clinicians in the fight against infectious diseases and for global health preparedness.

17 November 2025 in bioRxiv
Verified
Preprint
Open access
CKCaroline Koch
Caroline Koch
SSSeshagiri Sakthimani
Seshagiri Sakthimani
VNVictoria Noakes
Victoria Noakes
MCMiruna Cretu
Miruna Cretu
DNDavid Newman
David Newman
AIAleksandar Ivanov
Aleksandar Ivanov
Nanopore sensors offer exceptional sensitivity for detecting single molecules, making them ideal for early disease diagnostics. In this study, we present a multiplexed nanopore-based assay that combines DNA-barcoded probes with advanced computational analysis to detect microRNAs (miRNAs) with high specificity and quantitative accuracy. Each probe binds selectively to its target biomarker and generates a characteristic delay in the ionic current signal upon translocation through the nanopore, enabling label-free detection. We evaluated three analytical strategies for classifying delayed versus non-delayed events: (1) moving standard deviation (MSD), (2) spectral entropy (SE), and (3) a convolutional neural network (CNN). While MSD and SE rely on manually defined thresholds and exhibit limited sensitivity, the CNN model, trained on image representations of raw current traces, achieved near-perfect classification performance across all metrics. Grad-CAM visualisation confirmed that the CNN focused on biophysically relevant signal regions, enhancing interpretability and generalisability. All methods produced sigmoidal concentration-response curves consistent with expected binding kinetics, and nanopore-derived delay metrics closely matched RT-qPCR validation data. All three methods were capable of distinguishing between signal classes; however, the CNN model demonstrated superior sensitivity and robustness. This work highlights the importance of data interpretation in nanopore sensing and presents a comparative framework for binary event classification. The findings pave the way for the development of machine learning-driven nanopore diagnostics capable of detecting diverse biomarker types at the single-molecule level.